We are pleased to announce the appointment of Steve Slovick as a Managing Director in Puerto Rico. Throughout his 36-year career, Steve has demonstrated his expertise in pricing, commercial launch strategy, business development, market access, and exit strategies within the life science sector.
He started out as Senior Vice President in the early 2000’s for PriceSpective, a consulting firm that specialized in strategies to identify, capture, and communicate value for products, portfolios, and companies in the biopharmaceutical industry. PriceSpective was acquired by ICON Plc, where Steve was an important part of the acquisition process unlocking the synergies between the two companies maximizing financial value. His knowledge aligns with our mission at STS Capital, which is centered on helping our clients achieve Extraordinary Exits.
Steve’s entrepreneurial spirit led him to establish Jupiter Life Science Consulting in 2015. As CEO and Managing Partner, he led a dedicated team in providing commercial and market access strategies for global pharmaceutical, biotech, and medical device companies. His commitment to addressing complex market access challenges positioned Jupiter as a leading authority in the industry. In 2022, Jupiter was acquired by Red Nucleus where he stayed on as Managing Partner and President MACS to provide guidance and long-term partnership to life science clients worldwide.
Drawing from his firsthand experience of orchestrating successful exits, Steve offers a dual perspective as both a former business owner and a sell-side advisor. His comprehensive approach encompasses all aspects of the exit process, making him a valuable ally for business owners seeking a seamless transition.
Steve holds a Bachelor of Science in International Business and a Bachelor of Science in Marketing from the University of Colorado Boulder as well as a Master of Business Administration degree from Pepperdine Graziadio Business School.
“As a Managing Director at STS Capital Partners, Steve brings a wealth of experience and a track record of success to the table. With a career spanning decades, he has consistently demonstrated his ability to drive value and transformative initiatives within the pharmaceutical sector, aligning perfectly with our commitment to delivering maximum value and Extraordinary Exits for our clients.” Sean Friday, CEO of STS Capital Partners.